Pregled bibliografske jedinice broj: 1204874
COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
COVID-19 convalescent plasma as long-term therapy in immunodeficient patients? // 2021 Annual Meeting of Croatian Immunological Society
Trogir, Hrvatska, 2021. str. 46-46 (poster, domaća recenzija, sažetak, znanstveni)
CROSBI ID: 1204874 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
COVID-19 convalescent plasma as long-term therapy in
immunodeficient patients?
Autori
Rnjak, Dina ; Ravlić, Sanda ; Šola, Ana-Marija ; Halassy, Beata ; Šemnički , Joško ; Šuperba , Martina ; Hećimović , Ana ; Kurolt , Ivan- Christian ; Kurtović , Tihana ; Mačak Šafranko , Željka ; Zenić , Lucija ; Polančec , Denis ; Bendelja , Krešo ; Mušlin , Tatjana ; Jukić , Irena ; Vuk , Tomislav ; Artuković , Marinko
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Skup
2021 Annual Meeting of Croatian Immunological Society
Mjesto i datum
Trogir, Hrvatska, 23.09.2021. - 25.09.2021
Vrsta sudjelovanja
Poster
Vrsta recenzije
Domaća recenzija
Ključne riječi
passive antibody therapy ; convalescent plasma ; COVID-19 ; SARS-CoV-2 ; wild-type virus neutralization assay
Sažetak
The patients with hematological malignancies are a vulnerable group to COVID-19, due to the immunodeficiency resulting from the underlying disease and oncological treatment that significantly impair cellular and humoral immunity. Here we report on a beneficial impact of a passive immunotherapy with convalescent plasma to treat a prolonged, active COVID-19 in a patient with a history of nasopharyngeal diffuse large B- cell lymphoma treated with the therapy inducing substantial impairment of particularly humoral arm of immune system. The specific aim was to quantify SARS-CoV-2 neutralizing antibodies in a patient plasma during the course of therapy. Besides the standard of care treatment and monitoring, neutralizing antibody titers in patient's serum samples, calibrated according to the First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human), were quantified in a time- dependent manner. During the immunotherapy period peripheral blood flow cytometry immunophenotyping was conducted to characterize lymphocyte subpopulations. The phases of clinical improvements and worsening coincided with transfused neutralizing antibodies rises and drops in the patient's systemic circulation, proving their contribution in controlling the disease progress. Therapeutic approach based on convalescent plasma transfusion transformed a prolonged, active COVID-19 into a partly manageable chronic disease.
Izvorni jezik
Engleski
Znanstvena područja
Biologija, Temeljne medicinske znanosti, Kliničke medicinske znanosti, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
POVEZANOST RADA
Projekti:
HRZZ-IP-CORONA-IP-CORONA-2020-04-2053 - Stvaranje preduvjeta za uvođenje SARS-CoV-2 seroterapije u Hrvatskoj (Halassy, Beata, HRZZ - 2020-04) ( CroRIS)
MZOS-N/A - Centar izvrsnosti za virusnu imunologiju i cjepiva (CERVirVac) (Jonjić, Stipan, MZOS ) ( CroRIS)
Ustanove:
Klinika za infektivne bolesti "Dr Fran Mihaljević",
Hrvatski zavod za transfuzijsku medicinu,
Dječja bolnica Srebrnjak,
Sveučilište u Zagrebu
Profili:
Lucija Zenić
(autor)
Krešo Bendelja
(autor)
Tihana Kurtović
(autor)
Marinko Artuković
(autor)
Irena Jukić
(autor)
Beata Halassy
(autor)
Tomislav Vuk
(autor)
Ivan-Christian Kurolt
(autor)
Ana Hećimović
(autor)
Sanda Ravlić
(autor)
Denis Polančec
(autor)
Željka Mačak Šafranko
(autor)